Aptevo Therapeutics Inc

Juno Therapeutics, Inc, based in Seattle, WA, is a global biopharmaceutical company focused on developing innovative cell therapies to treat cancer and other serious diseases. With a strong commitment to research and collaboration, Juno Therapeutics is dedicated to advancing cutting-edge treatments to improve patient outcomes. Through strategic partnerships and a focus on scientific innovation, Juno Therapeutics is at the forefront of developing personalized therapies that aim to transform the lives of patients worldwide. Their dedication to advancing cell therapy and shaping the future of healthcare underscores their mission to build a better future through groundbreaking research and development.Generated from the website

Bristol Myers Squibb, a global biopharmaceutical company headquartered in Seattle, WA, is dedicated to pioneering innovations in cancer treatments to transform the lives of patients. Through strategic research approaches and a commitment to global inclusion and diversity, Bristol Myers Squibb is advancing cell therapy and shaping the future of healthcare. The company collaborates with partners worldwide to drive early innovation, conduct clinical trials, and develop cutting-edge medicines. Bristol Myers Squibb's mission is to provide patients with better outcomes and to lead the way in the discovery of new treatments for a variety of medical conditions.Generated from the website

Icosavax, Inc. is a clinical-stage biotechnology company based in Seattle, WA, dedicated to developing innovative vaccines using their unique virus-like particle (VLP) technology. Their VLPs are designed to mimic the structure of viruses, offering potential advantages such as a stronger immune response, broader coverage against related viral strains and mutations, longer durability, and easier combinability for multiple targets in one vaccine. With a focus on protecting vulnerable older adults from respiratory viruses, Icosavax aims to revolutionize the field of vaccines by creating a new era of immunization. Their cutting-edge approach has garnered attention, leading to an agreement to be acquired by AstraZeneca and positive interim Phase 2 results for their combination VLP vaccine candidate, IVX-A12, against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults.Generated from the website